Melphalan Hikma

Melphalan, the active ingredient in Melphalan Hikma, is an alkylating agent presented as a sterile powder for intravenous use. It is employed in the treatment of several cancers, including multiple myeloma, ovarian cancer, melanoma, neuroblastoma, and other solid tumors in adult patients.

GNH USA supplies Melphalan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use, through a reliable cold‑chain logistics network.

Melphalan is an alkylating antineoplastic agent used to treat a range of solid tumors and hematologic malignancies. - Multiple myeloma: induces remission and prolongs survival by eradicating malignant plasma cells. - Ovarian cancer: reduces tumor burden and improves response to subsequent therapies. - Melanoma: provides cytotoxic activity against metastatic lesions. - Neuroblastoma: contributes to disease control in high‑risk pediatric patients. - Other solid tumors: offers therapeutic benefit in various refractory cancers.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Decreased blood cell counts (myelosuppression) - Fatigue - Alopecia (hair loss)

Serious or Rare Side Effects: - Secondary malignancies (e.g., leukemia) - Pulmonary toxicity (interstitial pneumonitis) - Severe infections due to neutropenia

When using Melphalan, clinicians should observe several precautionary measures to minimize risks and ensure safe administration. - Monitor blood counts: perform regular complete blood count tests to detect myelosuppression. - Assess renal function: adjust therapy in patients with impaired kidney function. - Evaluate hepatic function: consider liver status before dosing. - Avoid use in patients with known hypersensitivity to melphalan or related compounds. - Use effective contraception: teratogenic potential requires reliable birth control for both sexes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: increases risk of severe myelosuppression. - Live vaccines: immunosuppression may lead to uncontrolled infection. - Strong CYP450 inducers (e.g., rifampin): may reduce melphalan exposure.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin): monitor renal function closely. - Hepatotoxic agents (e.g., azole antifungals): watch for liver enzyme elevations. - Anticoagulants (e.g., warfarin): increased bleeding risk may require dose adjustment.